BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Chen Z, Zhang Y, Yuan P, Liu J, Ding L, Ye Q. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett 2021;519:161-71. [PMID: 34303763 DOI: 10.1016/j.canlet.2021.07.029] [Reference Citation Analysis]
2 Li S, Huang J, Yang F, Zeng H, Tong Y, Li K. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma. Sci Rep 2021;11:11078. [PMID: 34040099 DOI: 10.1038/s41598-021-90507-w] [Reference Citation Analysis]
3 Liu C, Huang R, Yu H, Gong Y, Wu P, Feng Q, Li X. Fuzheng Xiaozheng prescription exerts anti-hepatocellular carcinoma effects by improving lipid and glucose metabolisms via regulating circRNA-miRNA-mRNA networks. Phytomedicine 2022;103:154226. [DOI: 10.1016/j.phymed.2022.154226] [Reference Citation Analysis]
4 Luo YY, Tao KG, Lu YT, Li BB, Wu KM, Ding CH, Yan FZ, Liu Y, Lin Y, Zhang X, Zeng X. Hsa_Circ_0098181 Suppresses Hepatocellular Carcinoma by Sponging miR-18a-3p and Targeting PPARA. Front Pharmacol 2022;13:819735. [PMID: 35264957 DOI: 10.3389/fphar.2022.819735] [Reference Citation Analysis]
5 He RQ, Li JD, Du XF, Dang YW, Yang LJ, Huang ZG, Liu LM, Liao LF, Yang H, Chen G. LPCAT1 overexpression promotes the progression of hepatocellular carcinoma. Cancer Cell Int 2021;21:442. [PMID: 34419067 DOI: 10.1186/s12935-021-02130-4] [Reference Citation Analysis]
6 Ahmed N, Ahmed N, Pezacki JP. miR-383 Regulates Hepatic Lipid Homeostasis and Response to Dengue Virus Infection. ACS Infect Dis 2022;8:928-41. [PMID: 35254825 DOI: 10.1021/acsinfecdis.1c00470] [Reference Citation Analysis]
7 Ferramosca A, Zara V. Mitochondrial Carriers and Substrates Transport Network: A Lesson from Saccharomyces cerevisiae. Int J Mol Sci 2021;22:8496. [PMID: 34445202 DOI: 10.3390/ijms22168496] [Reference Citation Analysis]
8 Meng H, Shen M, Li J, Zhang R, Li X, Zhao L, Huang G, Liu J. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. Eur J Pharmacol 2021;906:174280. [PMID: 34174265 DOI: 10.1016/j.ejphar.2021.174280] [Reference Citation Analysis]
9 Balgoma D, Kullenberg F, Calitz C, Kopsida M, Heindryckx F, Lennernäs H, Hedeland M. Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. Cells 2021;10:1163. [PMID: 34064765 DOI: 10.3390/cells10051163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang Q, Tan Y, Jiang T, Wang X, Li Q, Li Y, Dong L, Liu X, Xu G. Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma. Cells 2022;11:1066. [PMID: 35406630 DOI: 10.3390/cells11071066] [Reference Citation Analysis]
11 Wu X, Lan T, Li M, Liu J, Wu X, Shen S, Chen W, Peng B. Six Metabolism Related mRNAs Predict the Prognosis of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2021;8:621232. [PMID: 33869278 DOI: 10.3389/fmolb.2021.621232] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wen Tan SL, Israeli E, Ericksen RE, Chow PK, Han W. The altered lipidome of hepatocellular carcinoma. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wu J, Xue R, Jiang RT, Meng QH. Characterization of metabolic landscape in hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(9): 1144-1156 [PMID: 34616519 DOI: 10.4251/wjgo.v13.i9.1144] [Reference Citation Analysis]
14 Kim J, Kwon H, Kalsoom F, Sajjad MA, Lee HW, Lim JH, Jung J, Chwae Y, Park S, Shin H, Kim K. Ca2+/Calmodulin-Dependent Protein Kinase II Inhibits Hepatitis B Virus Replication from cccDNA via AMPK Activation and AKT/mTOR Suppression. Microorganisms 2022;10:498. [DOI: 10.3390/microorganisms10030498] [Reference Citation Analysis]
15 Wang Y, Wang Y, Chen C, Ren F, Cao R, Wang Y, Han P, Zhang X, Xu C, Liu X, Xu G. Serum lipid profiling analysis and potential marker discovery for ovarian cancer based on liquid chromatography-Mass spectrometry. J Pharm Biomed Anal 2021;199:114048. [PMID: 33836461 DOI: 10.1016/j.jpba.2021.114048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang W, Zhang C, Yu Q, Zheng X, Yin C, Yan X, Liu G, Song Z. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients. BMC Gastroenterol 2021;21:68. [PMID: 33579192 DOI: 10.1186/s12876-021-01638-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Valiakou V, Eliadis P, Karamichali E, Tsitsilonis O, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. Int J Mol Sci 2021;22:7961. [PMID: 34360721 DOI: 10.3390/ijms22157961] [Reference Citation Analysis]
18 Shueng PW, Chan HW, Lin WC, Kuo DY, Chuang HY. Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism. Int J Mol Sci 2022;23:6501. [PMID: 35742944 DOI: 10.3390/ijms23126501] [Reference Citation Analysis]
19 [DOI: 10.1101/2021.01.28.428684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Zhou B, Wang J, Gao J, Xie J, Chen Y. Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma. Int J Med Sci 2020;17:2888-94. [PMID: 33162817 DOI: 10.7150/ijms.49913] [Reference Citation Analysis]
21 Soukupova J, Malfettone A, Bertran E, Hernández-Alvarez MI, Peñuelas-Haro I, Dituri F, Giannelli G, Zorzano A, Fabregat I. Epithelial-Mesenchymal Transition (EMT) Induced by TGF-β in Hepatocellular Carcinoma Cells Reprograms Lipid Metabolism. Int J Mol Sci 2021;22:5543. [PMID: 34073989 DOI: 10.3390/ijms22115543] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Lin T, Zhang E, Lin Z, Peng L. Comprehensive Analysis of LPCATs Highlights the Prognostic and Immunological Values of LPCAT1/4 in Hepatocellular Carcinoma. Int J Gen Med 2021;14:9117-30. [PMID: 34876845 DOI: 10.2147/IJGM.S344723] [Reference Citation Analysis]
23 Zuo D, An H, Li J, Xiao J, Ren L. The Application Value of Lipoprotein Particle Numbers in the Diagnosis of HBV-Related Hepatocellular Carcinoma with BCLC Stage 0-A. J Pers Med 2021;11:1143. [PMID: 34834495 DOI: 10.3390/jpm11111143] [Reference Citation Analysis]
24 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
25 Xu B, Chen L, Zhan Y, Marquez KNS, Zhuo L, Qi S, Zhu J, He Y, Chen X, Zhang H, Shen Y, Chen G, Gu J, Guo Y, Liu S, Xie T. The Biological Functions and Regulatory Mechanisms of Fatty Acid Binding Protein 5 in Various Diseases. Front Cell Dev Biol 2022;10:857919. [DOI: 10.3389/fcell.2022.857919] [Reference Citation Analysis]
26 Li W, Chen H, Qian Y, Wang S, Luo Z, Shan J, Kong X, Gao Y. Integrated Lipidomics and Metabolomics Study of Four Chemically Induced Mouse Models of Acute Intrahepatic Cholestasis. Front Pharmacol 2022;13:907271. [PMID: 35754480 DOI: 10.3389/fphar.2022.907271] [Reference Citation Analysis]
27 Wang MD, Wang NY, Zhang HL, Sun LY, Xu QR, Liang L, Li C, Huang DS, Zhu H, Yang T. Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathway. Oncogenesis 2021;10:74. [PMID: 34772914 DOI: 10.1038/s41389-021-00364-5] [Reference Citation Analysis]
28 Huang C, Li Y, Wang K, Xi J, Xu Y, Si X, Pei D, Lyu S, Xia G, Wang J, Li P, Ye H, Xing Y, Wang Y, Huang J. Analysis of lipidomics profile of Carya cathayensis nuts and lipid dynamic changes during embryonic development. Food Chem 2021;370:130975. [PMID: 34507207 DOI: 10.1016/j.foodchem.2021.130975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
29 Sangineto M, Bukke VN, Bellanti F, Tamborra R, Moola A, Duda L, Villani R, Romano AD, Serviddio G. A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model. Nutrients 2021;13:652. [PMID: 33671262 DOI: 10.3390/nu13020652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Li M, Hu J, Jin R, Cheng H, Chen H, Li L, Guo K. Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:361-76. [PMID: 33324588 DOI: 10.2147/JHC.S279123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Frohlich J, Mazza T, Sobolewski C, Foti M, Vinciguerra M. GDF11 rapidly increases lipid accumulation in liver cancer cells through ALK5-dependent signaling. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158920. [PMID: 33684566 DOI: 10.1016/j.bbalip.2021.158920] [Reference Citation Analysis]
32 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
33 Castro-Gil MP, Sánchez-Rodríguez R, Torres-Mena JE, López-Torres CD, Quintanar-Jurado V, Gabiño-López NB, Villa-Treviño S, Del-Pozo-Jauner L, Arellanes-Robledo J, Pérez-Carreón JI. Enrichment of progenitor cells by 2-acetylaminofluorene accelerates liver carcinogenesis induced by diethylnitrosamine in vivo. Mol Carcinog 2021;60:377-90. [PMID: 33765333 DOI: 10.1002/mc.23298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Monroe JD, Fraher D, Huang X, Mellett NA, Meikle PJ, Sinclair AJ, Lirette ST, Maihle NJ, Gong Z, Gibert Y. Identification of novel lipid biomarkers in xmrk- and Myc-induced models of hepatocellular carcinoma in zebrafish. Cancer Metab 2022;10:7. [PMID: 35379333 DOI: 10.1186/s40170-022-00283-y] [Reference Citation Analysis]
35 Tanase DM, Gosav EM, Petrov D, Jucan AE, Lacatusu CM, Floria M, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Diagnostics (Basel) 2021;11:2053. [PMID: 34829402 DOI: 10.3390/diagnostics11112053] [Reference Citation Analysis]
36 Zhang T, Zhang Y, Liu J, Ma Y, Ye Q, Yan X, Ding L. MicroRNA-377-3p inhibits hepatocellular carcinoma growth and metastasis through negative regulation of CPT1C-mediated fatty acid oxidation. Cancer Metab 2022;10. [DOI: 10.1186/s40170-021-00276-3] [Reference Citation Analysis]